Managing Partner at Kurma. Scientist by training, Vanessa started joined the Paris based VC fund CDC-Innovation in 1998 as an analyst, prior to joining a California based start up to be in charge of the business development activities. Vanessa then joined Ipsen in 2003, as Strategic Advisor to the CEO and headed the portfolio management team for the gastro-enterology product range (totaling more than 130M€). Vanessa was appointed in 2005 as Product Manager and Team Leader for febuxostat (Adenuric), which received EMA approval in 2008. Vanessa was then successively appointed as Senior Director, Business Development Oncology in 2009 and VP, R&D Strategic Planning in 2011. Vanessa graduated in Biology at Ecole Normale Superieure, Cachan and in Immunology at Pasteur Institute. Vanessa joined Kurma in September 2013 and is responsible for the investment in Xeltis (Switzerland), Asceneuron (Switzerland), Step Pharam (France) and Vivet Therapeutics (France).